ASCENTRA-UC expected to enroll up to 204 patients with moderately to severely active ulcerative colitis across North America ...
Merck & Co Inc. MRK on Monday said its investigational therapy tulisokibart achieved the primary endpoint in a Phase 3 study in moderately to severely active ulcerative colitis (UC), marking what the ...
Abivax Reports Positive ABTECT Maintenance Part 2 Results for Obefazimod, Demonstrating Meaningful Clinical Benefit in Refractory Ulcerative ...
DUBLIN--(BUSINESS WIRE)--The "Ulcerative Colitis (UC) - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering. Ulcerative Colitis (UC) Pipeline Insight, 2020 ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 3 ATLAS-UC induction-only study (Study 2) evaluating tulisokibart ...
"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this 12-part journey through a disease state ...
When you have ulcerative colitis (UC), monitoring your symptoms, diet, exercise, medication, and personal well-being is vital. Smartphone tracking apps can help. “The information these tracking apps ...
Holidays and other celebrations are a time to slow down and enjoy yourself with family and friends. Many times, they also include lots of delicious foods and drinks. For people living with an ...
Ulcerative colitis (UC) is a chronic disease that causes inflammation and sores in the lining of your colon. It’s a complicated disease that can interfere with your quality of life. You may miss days ...
"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this 12-part journey through a disease state ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results